Trials / Unknown
UnknownNCT04119219
Antiangiogenic Therapy of CNV Associated With Angioid Streaks
Collaborative Ocular Antiangiogenic Study of Ukraine. Multicentral, Open-label, Randomized, Prospective Study of Antiangiogenic Therapy of Choroidal Neovascularisation Associated With Angioid Streaks
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- The Filatov Institute of Eye Diseases and Tissue Therapy · Academic / Other
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the effectiveness of antiangiogenic therapy to choroidal neovascularization secondary to angioid streaks.
Detailed description
The purpose of this study is to determine the effectiveness of antiangiogenic therapy to choroidal neovascularization secondary to angioid streaks. This study is planned as a follow-up. Patients with angioid streaks included in it will receive antiangiogenic therapy in accordance with the approved indications for use indicated in the instructions for the use of drugs in Ukraine. The treatment proposed in this study is based on the world experience and scientific developments of the Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine ". Therefore, it is expected that the benefit / risk ratio in relation to the participation in this study should not be different from that described in the scientific literature and the benefits outweigh the risk. It is known that the absence of treatment in these diseases leads to an irreparable loss of central vision.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Intravitreal injection | Intravitreal injection to the regimen pro re nata. |
Timeline
- Start date
- 2018-03-27
- Primary completion
- 2021-12-31
- Completion
- 2022-01-31
- First posted
- 2019-10-08
- Last updated
- 2021-02-03
Locations
3 sites across 1 country: Ukraine
Source: ClinicalTrials.gov record NCT04119219. Inclusion in this directory is not an endorsement.